Telomir Director Matthew Del Giudice Receives 50,000-Option Award

What Happened
Matthew Paul Del Giudice, a director of Telomir Pharmaceuticals (TELO), was granted 50,000 stock options on April 16, 2026. The Form 4 reports the award as a derivative acquisition (code A) with a reported acquisition value of $0. Per the filing, the options vested immediately and the exercise price was set equal to the closing price of Telomir common stock on the grant date (so the options had no intrinsic value at grant).

Key Details

• Transaction date: 2026-04-16 (grant of 50,000 options).
• Reported acquisition value on Form 4: $0; exercise price = closing price on 4/16/2026 (per footnote).
• Vesting: All options vested immediately upon issuance (per footnote).
• Filing date: 2026-07-27 (Form 4 filed more than three months after the transaction), which is later than the usual two-business-day reporting window.
• Shares/options owned after transaction: Not specified in the provided filing excerpt.
• Transaction type/code: Grant/award of derivative securities (A).

Context
This was an equity award, not a purchase or sale—no shares were sold or bought on the open market and no immediate cash changed hands. Because the exercise price equals the stock’s close on the grant date, the options had no in-the-money value at issuance; they gain value only if the stock rises above the exercise price before expiration. The late filing reduces the timeliness of disclosure but does not change the nature of the award.